In general, these results collectively demonstrated that miR-16-5p has almost identical YTHDF1-inhibitory functions compared to siRNA-based YTHDF1 knockdown to suppress the malignancy features of breast cancer cells and induce apoptosis, potentiating the application of miR-16-5p as a therapeutic modality to target the YTHDF1 expression in breast cancer cells for efficient tumor inhibition. The gene discussed is YTHDF1; the disease is breast carcinoma.